

1 **Relationship between circulating FSH levels and body composition and bone health in patients with**  
2 **prostate cancer who undergo androgen deprivation therapy. The BLADE study.**

3 Bergamini M<sup>1</sup>, Dalla Volta A<sup>1</sup>, Palumbo C<sup>2</sup>, Zamboni S<sup>3</sup>, Triggiani L<sup>4</sup>, Zamparini M<sup>1</sup>, Laganà M<sup>1</sup>, Rinaudo L<sup>5</sup>, Di  
4 Meo N<sup>6</sup>, Caramella I<sup>1</sup>, Bresciani R<sup>7</sup>, Valcamonico F<sup>1</sup>, Borghetti P<sup>4</sup>, Guerini A<sup>4</sup>, Farina D<sup>6</sup>, Antonelli A<sup>8</sup>, Simeone  
5 C<sup>3</sup>, Mazziotti G<sup>9,10</sup>, Berruti A<sup>1</sup>.

6 1. Medical Oncology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological  
7 Sciences and Public Health, University of Brescia, Piazzale Spedali Civili 1, 25123, Brescia, Italy.

8 2. Division of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore  
9 Della Carità Hospital, Novara, Italy.

10 3. Urology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences  
11 and Public Health, University of Brescia, Brescia, Italy.

12 4. Radiation Oncology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological  
13 Sciences and Public Health, University of Brescia, Brescia, Italy.

14 5. Tecnologie Avanzate S.r.l., Turin, Italy.

15 6. Radiology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences  
16 and Public Health, University of Brescia, Brescia, Italy.

17 7. Division of Biotechnology, Department of Molecular and Translational Medicine (DMTM), University of  
18 Brescia, Brescia, Italy.

19 8. Urology Unit, AOUI Verona, Department of Surgery, Dentistry, Pediatrics and Gynecology, University of  
20 Verona, Verona, Italy.

21 9. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy.

22 10. Endocrinology, Diabetology and Medical Andrology Unit, Metabolic Bone Diseases and Osteoporosis  
23 Section, IRCCS Humanitas Research Hospital, Rozzano-Milan Italy.

24

25 **Correspondence to:**

26 Gherardo Mazziotti  
27 Department of Biomedical Sciences  
28 Humanitas University  
29 Via Rita Levi Montalcini 4  
30 20072 Pieve Emanuele, Milan  
31 Italy

32

33

34 Alberto Dalla Volta  
35 Medical Oncology Unit  
36 ASST-Spedali Civili  
37 Piazzale Spedali Civili 1  
38 25123 Brescia  
39 Italy

40

41

42 **Key words:** prostate cancer patients, androgen deprivation, FSH, body composition, bone health

43 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 44 **Abstract**

45 *Background:* Amongst its extragonadal effects, Follicle-Stimulating Hormone (FSH) has an impact on body  
46 composition and bone metabolism. Since androgen deprivation therapy (ADT) has a profound impact on  
47 circulating FSH concentrations, this hormone could potentially be implicated in the changes of fat body  
48 mass (FBM), lean body mass (LBM) and bone fragility induced by ADT. The objective of this study is to  
49 correlate FSH serum levels with body composition parameters, bone mineral density (BMD) and bone  
50 turnover markers at baseline conditions and after 12 months of ADT.

51 *Methods:* 29 consecutive non-metastatic prostate cancer (PC) patients were enrolled from 2017 to 2019 in  
52 a phase IV study. All patients underwent administration of the Luteinizing Hormone-Releasing Hormone  
53 antagonist degarelix. FBM, LBM and BMD were evaluated by dual-energy x-ray absorptiometry at baseline  
54 and after 12 months of ADT. FSH, alkaline phosphatase (ALP) and C-terminal telopeptide of type I collagen  
55 (CTX) were assessed at baseline and after 6 and 12 months. For outcome measurements and statistical  
56 analysis, T-test or sign test and Pearson or Spearman tests for continuous variables were used when  
57 indicated.

58 *Results:* At baseline conditions, a weak, non-significant, direct relationship was found between FSH serum  
59 levels and FBM at arms ( $r=0.36$ ) and legs ( $r=0.33$ ). Conversely, a stronger correlation was observed between  
60 FSH and total FBM ( $r=0.52$ ,  $p=0.006$ ), fat mass at arms ( $r=0.54$ ,  $p=0.004$ ) and fat mass at trunk ( $r=0.45$ ,  
61  $p=0.018$ ) assessed after 12 months. On the other hand, an inverse relationship between serum FSH and  
62 appendicular lean mass index (ALMI)/FBM ratio was observed ( $r=0.64$ ,  $p=0.001$ ). This is an ancillary study of  
63 a prospective trial and this is the main limitation.

64 *Conclusions:* FSH serum levels after ADT could have an impact on body composition, in particular on fat  
65 body mass. Therefore, FSH could be a promising marker to monitor the risk of sarcopenic obesity and  
66 cardiovascular complications in PC patients undergoing ADT.

67 *Funding:* this research was partially funded by Ferring Pharmaceuticals. The funder had no role in  
68 design and conduct of the study, collection, management, analysis, and interpretation of the data  
69 and in preparation, review, or approval of the manuscript.

70  
71 *Clinical trial number:* [clinicalTrials.gov NCT03202381](https://clinicaltrials.gov/ct2/show/study/NCT03202381), EudraCT Number 2016-004210-10.  
72

## 73 **Introduction**

74 Recent preclinical and clinical studies have shown that Follicle-Stimulating Hormone (FSH) exerts effects  
75 beyond those on gonadal tissue, which have been known for a long time (Lizneva et al. 2019). In the animal  
76 model, FSH has been observed to stimulate osteoclastic activity and therefore to exert a negative role on  
77 bone mass (Sun et al. 2006; Zaidi et al. 2023; Gera et al. 2022). Furthermore, FSH was found to have a  
78 positive action on adipocytes and the blockade of FSH induced by antibodies against FSH receptor caused  
79 an increase in bone mass and a reduction of body fat (Liu et al. 2017; Rojekar et al. 2023). These preclinical  
80 data were confirmed in clinical studies. Large epidemiologic data have shown significant reductions in bone  
81 mineral density (BMD) and high resorption rates ~2-3 years prior to menopause, when FSH serum levels  
82 are increasing, which is also associated with increased body weight and visceral adiposity (Thurston et al.  
83 2009; Senapati et al. 2014). A longitudinal study involving post-menopausal women has shown that  
84 increases in circulating FSH levels were associated with greater increases in the percentage of total body  
85 fat, total body fat mass and subcutaneous adipose tissue (Mattick et al. 2022). Moreover, clinical studies  
86 have found that FSH is also involved in the modulation of lean mass. A large cohort study of  
87 perimenopausal women showed that increased FSH concentrations were associated with increasing fat  
88 mass and decreasing lean mass measured by bioelectrical impedance analysis (Sowers et al. 2007). Another  
89 recent prospective study showed that the indicators of sarcopenia were strongly associated with  
90 gonadotropins levels, especially in older men (Guligowska et al. 2021). The impact of FSH on body

91 composition may at least partially explain the observed correlation between FSH levels and the risk of  
92 cardiovascular events (Munir et al. 2012; Celestino Catão Da Silva et al. 2013; El Khoudary et al. 2016).

93 Studies clarifying the relationship among FSH, body composition measures and BMD in prostate cancer (PC)  
94 patients are lacking. Likewise, the interaction between the variation of FSH serum levels and the  
95 modification of these parameters in PC patients undergoing androgen deprivation therapy (ADT) is not  
96 known.

97 We recently conducted the BLADE study (Bone mineral mAss Dexa dEgarelix), a prospective phase IV study  
98 designed to obtain explorative information on dual-energy x-ray absorptiometry (DXA) measurement  
99 changes in lean body mass (LBM) and fat body mass (FBM) in patients with non-metastatic PC treated with  
100 degarelix. Data on changes in total LBM and FBM and on the impact of degarelix on BMD and bone  
101 turnover markers were recently published (Palumbo et al. 2021; Palumbo et al. 2022).

102 Here we analyse the association of FSH with DXA-assessed FBM, LBM and BMD and bone turnover markers  
103 at baseline and after degarelix administration in the patients enrolled in the BLADE study.

104

## 105 **Patients and methods**

### 106 *Trial design and endpoints*

107 BLADE is a single-centre, prospective, interventional phase IV study (clinicalTrials.gov NCT03202381,  
108 EudraCT Number 2016-004210-10) conducted at the Prostate Cancer Unit of the Azienda Socio Sanitaria  
109 Territoriale degli Spedali Civili and Università degli Studi of Brescia. The study was carried out in accordance  
110 with the Declaration of Helsinki Principles and Good Clinical Practices and was approved by the Ethics  
111 Committee of Brescia (approval number NP2540). All patients provided a written informed consent. Male  
112 patients with histologically confirmed PC without bone metastasis at bone scintigraphy, judged eligible to  
113 ADT according to current guidelines recommendations (Cornford et al. 2017; Mottet et al. 2017) after a  
114 multidisciplinary discussion, were enrolled. Eligibility criteria have been published elsewhere (Palumbo, et  
115 al. 2021). Degarelix was administered as a subcutaneous injection with a starting dose of 240 mg, followed  
116 by a maintenance dose of 80 mg every 28 days. After 12 months, treatment with degarelix was continued  
117 as clinically indicated. DXA measurements for assessing BMD and body composition parameters were  
118 performed at baseline and after 12 months, using Hologic QDR-4500W instrumentation (Hologic  
119 Corporation, Waltham, Massachusetts).

### 120 *Assessment of regional lean body mass and fat body mass by dual x-ray absorptiometry*

121 DXA measurements related to whole body DXA scans were extracted from Apex Software version 3.4.

122 The densitometric image of each patient was divided, following the manufacturer's instructions, into  
123 different body districts, including arms, legs, trunk, head and other derived regions, such as the android and  
124 gynoid zone.

125 BMD, bone mineral content (BMC), Fat Free Mass and Fat mass were assessed for every region of interest,  
126 where Fat Free Mass was provided by the software in terms of lean soft tissue plus BMC. Despite the lean  
127 mass measured by DXA counts also skin, connective tissue and some lean components within the adipose  
128 tissue (Visser et al. 1999), it still correlates highly with computed tomography and magnetic resonance  
129 imaging measurements and represents a good approximation of the real muscle mass (Buckinx et al. 2018).

130 Other DXA derived body composition parameters, such as fat mass index (FM/H<sup>2</sup>) (FMI), appendicular lean  
131 mass index (ALM/H<sup>2</sup>) (ALMI) and Trunk/Appendicular ratio, were then calculated to complete the analysis  
132 and the patient characterization.

133 *Circulating bone turnover markers*

134 Blood chemistry and bone turnover markers: alkaline phosphatase (ALP) and C-terminal telopeptide of type  
135 I collagen (CTX) were assessed at baseline, 6 and 12 months. CTX serum levels were measured using the  
136 ElectroChemiLuminescenceAssay (ECLIA) kit Elecsys beta-CrossLaps/serum (Roche Diagnostic, Germany)  
137 using Cobas e411instruments (Roche); normal ranges were < 0.704 ng/ml (men of the age between 50-70),  
138 < 0.854 ng/ml (men > 70) with a repeatability CV% of 2.6. Bone-ALP serum levels were determined in a  
139 twostep procedure. Briefly, total ALP serum activity was measured using the colorimetric method ALP2  
140 (Roche) using Cobas c701 instruments (Roche); normal ranges were 50-116 U/L +/- 0.6 with a repeatability  
141 CV% of 0.7. Samples were then subjected to electrophoretic separation to separate the different ALP  
142 isoforms using the G26 automated system (Sebia, France) equipped with the Interlab specific kit (Italy).  
143 Bone-ALP activity was calculated as fraction of the total ALP activity related to the percentage of  
144 densitometric analysis of the electrophoretic migration

145 *Statistical analysis*

146 The normal distribution of continuous variables was tested with the Shapiro-Wilk test. Differences between  
147 parameters at baseline and 12 months were computed as percentage changes. To test if these changes  
148 were significantly different from 0 we used one sample t-test, or alternatively the non-parametric sign test.

149 Correlations between variables either at baseline and 12 months were expressed as Pearson's r (or  
150 alternatively with Spearman R, for variables not normally distributed).

151 We considered a significant threshold of  $p < 0.05$ , and to control for possible false positive results we  
152 applied the Bonferroni correction ( $p' = \frac{p}{k}$ , where k is the number of hypotheses tested). Given that Type I  
153 errors cannot decrease (the whole point of Bonferroni adjustments) without inflating type II errors  
154 (Perneger 1998), significant results in the raw test but which do not remain so after correction will still be  
155 mentioned.

156 Statistics were performed using R and SPSS (IBM Corp. Released 2015. IBM SPSS Statistics for Windows,  
157 Version 23.0. Armonk, NY: IBM Corp.)

158

159 **Results**

160 Twenty-nine patients were included in the BLADE study and their characteristics have been described  
161 elsewhere (Palumbo, et al. 2022). The consort diagram is reported in supplementary material (Figure 1S).

162 Mean FSH serum levels at baseline conditions were 11.9 UI/L (95% Confidence Intervals [CIs]: 7.6 to 16.3).

163 Mean FSH serum levels significantly decreased to 1.45 UI/L (95% CIs: 1.01 to 1.89) after 6 months of  
164 degarelix treatment and to 2.4 UI/L (95% CIs: 1.4 to 3.4) after 12 months. The corresponding percent  
165 changes were -77.59% (95% CIs: -86.20 to -68.87) and -59.7% (95% CIs: -80.3 to -39.1,  $p < 0.001$ ) (**Figure 1**).

166 Data on changes in body composition parameters, BMD and bone turnover markers have been published  
167 elsewhere (Palumbo, et al. 2021; Palumbo, et al. 2022; Dalla Volta et al. 2023). Correlations between FSH

168 changes and changes in body composition parameters, BMD and bone turnover markers were not  
169 statistically significant, so these data are not presented.

#### 170 *Relationship between FSH serum levels and body composition, BMD and bone turnover markers at baseline*

171 At baseline conditions no relationship was found between FSH serum levels and the following DXA-derived  
172 parameters: BMD at left hip and spine, total FBM, total LBM, lean mass at arms and legs, ALMI, ALMI/FBM  
173 ratio and android/gynoid ratio. No correlation was also found between FSH serum levels and serum levels  
174 of either ALP or CTX. A direct relationship, although not significant, was found between FSH serum levels  
175 and FBM at arms ( $r=0.36$ ) and legs ( $r=0.33$ ) (**Table 1**).

#### 176 *Relationship between FSH serum levels and body composition, BMD and bone turnover markers after 12 177 months of degarelix treatment*

178 The correlation between circulating FSH levels at 6 and 12 months, bone turnover markers evaluated at the  
179 same time, BMD and body composition parameters assessed after 12 months is shown in **Table 2**. FSH  
180 serum levels assessed after 6 months of degarelix administration showed a direct relationship with total  
181 FBM ( $r=0.49$ ,  $p=0.008$ ) and with fat mass evaluated at arms ( $r=0.53$ ,  $p=0.004$ ), trunk ( $r=0.48$ ,  $p=0.009$ ) and  
182 legs ( $r=0.45$ ,  $p=0.015$ ). By contrast, FSH serum levels after 6 months of treatment showed an inverse  
183 relationship with ALMI/FBM ratio ( $r=-0.58$ ,  $p=0.001$ ). FSH measured after 12 months maintained a  
184 significant relationship with total FBM ( $r=0.52$ ,  $p=0.006$ ) (**Figure 2A**), fat mass at arms ( $r=0.54$ ,  $p=0.004$ )  
185 (**Figure 2B**) and fat mass at trunk ( $r=0.45$ ,  $p=0.018$ ) (**Figure 2C**). The relationship between FSH and fat mass  
186 at legs lost the statistical significance ( $r=0.33$ ,  $p=0.089$ ), while the inverse relationship with ALMI/FBM ratio  
187 was confirmed ( $r=0.64$ ,  $p=0.001$ ) (**Figure 2D**).

188

## 189 **Discussion**

190 ADT in PC patients leads to an increase in fat mass and to a decrease in lean mass, thus increasing the risk  
191 of sarcopenic obesity. In addition, ADT has also a negative impact on skeletal fragility, which increases the  
192 risk of fractures. During the recent years, there has been consistent evidence that alterations in body  
193 composition could contribute to determine skeletal fragility in patients under ADT, such as well  
194 demonstrated in other forms of male hypogonadism (Vena et al. 2022). However, the determinants of  
195 altered body composition in male hypogonadism and in ADTs have not been completely defined. As a  
196 matter of fact, low testosterone values do not seem to be the only determinant of sarcopenic obesity in  
197 males with hypogonadism. In this context, FSH values might play a role. In fact, amongst its extragonadal  
198 effects, FSH directly affects adipogenesis, lean mass and bone turnover (Liu, et al. 2017; Rojekar, et al.  
199 2023; Zaidi, et al. 2023; Gera, et al. 2022).

200 As demonstrated in other studies prospectively evaluating circulating FSH levels after treatment with  
201 Luteinizing Hormone-Releasing Hormone (LHRH) agonists and antagonists (Klotz et al. 2008), degarelix  
202 administration consistently reduced FSH values. Therefore, it is reasonable to hypothesize that this  
203 hormone is involved in the mechanisms that underlie ADT impact on body composition and skeletal  
204 fragility.

205 This ancillary analysis of the BLADE study shows that FSH serum levels correlated with fat mass in basal  
206 conditions, albeit not significantly. However, either total fat mass and fat mass in the upper limbs and trunk  
207 significantly correlated with FSH values after 12 months of degarelix therapy.

208 Even more interesting, when assessed after degarelix, FSH levels inversely correlated with ALMI/FBM ratio,  
209 a parameter that identifies patients at high risk for sarcopenic obesity. These data suggest that sexual  
210 hormones counteract FSH effect on body composition at baseline conditions, whereas this effect becomes  
211 more evident after ADT.

212 It is noteworthy that FSH values and body composition parameters after 12 months of degarelix therapy  
213 achieved a significant correlation, despite the narrow range of FSH levels (**Figure 1**). According to these  
214 data, small changes in FSH can result in significant changes in body composition in a condition of androgen  
215 and estrogen deprivation.

216 It is known that one of the most noticeable differences of LHRH-antagonists compared to LHRH-agonists  
217 are FSH levels during therapy, which are mildly higher with LHRH-agonists compared to LHRH-antagonists.  
218 According to our data, PC patients treated with LHRH-antagonists may experience less body composition  
219 changes due to lower FSH residual values (Klotz, et al. 2008; Margel et al. 2019; Abufaraj et al. 2021).

220 Unlike other settings, FSH values before and after degarelix did not correlate with either BMD or bone  
221 turnover markers.

222 To our knowledge, this is the first study showing an association between circulating FSH levels and body  
223 composition in PC patients undergoing ADT. However, this study suffers from all the limitations of ancillary  
224 studies. Therefore, the results obtained are to be considered as hypothesis-generating and cannot be  
225 generalized.

226 In conclusion, the findings of this study suggest that FSH serum levels after ADT could impact body  
227 composition - fat body mass in particular - in PC patients undergoing ADT.

228 Of course further investigation is required to establish the association between FSH serum levels, measured  
229 during ADT, and sarcopenic obesity risk in PC patients. However, this is an area of great interest.

230 FSH could be a promising marker in monitoring PC patients during ADT in order to identify those who are  
231 more vulnerable and at greater risk of cardiovascular complications.

232

### 233 **Statements**

234 *Ethical approval:* the study was carried out in accordance with the Declaration of Helsinki Principles and  
235 Good Clinical Practices and was approved by the Ethics Committee of Brescia (approval number NP2540).  
236 All patients provided a written informed consent.

237

238 *Funding:* this research was partially funded by Ferring Pharmaceuticals. The funder had no role in  
239 design and conduct of the study, collection, management, analysis, and interpretation of the data  
240 and in preparation, review, or approval of the manuscript.

241

242 *Conflict of interest statement:* Alberto Dalla Volta received grants from Janssen Cylag, Ipsen, support for  
243 attending meetings and fee for board from Janssen Cylag; Luca Triggiani received honoraria from Astellas,  
244 Janssen and Bayer, support for attending meeting from Janssen; Luca Rinaudo is affiliated with Tecnologie  
245 Avanzate S.r.l., the author has no financial interests to declare; Paolo Borghetti received honoraria for  
246 lectures from Astrazeneca and Roche; Andrea Guerini received support for attending meeting from Elekta;  
247 Davide Farina received consulting fees from Siemens Healthineers; Alessandro Antonelli received payments  
248 for clinical trial from Janssen, fees for advisory board from Astra Zeneca, Ipsen, Photocure, Teleflex;  
249 Gherardo Mazziotti received fee for preceptorship from Amgen UCB; Alfredo Berruti received consulting  
250 fee from Ferring Pharmaceuticals; Marco Bergamini, Carlotta Palumbo, Stefania Zamboni, Manuel  
251 Zamparini, Marta Laganà, Nunzia Di Meo, Irene Caramella, Roberto Bresciani, Francesca Valcamonico and  
252 Claudio Simeone declare that they have no conflict of interest.



253

254 *Acknowledgements*: the authors are grateful to the following associations: AOB (Associazione  
255 Oncologica Bresciana) and FIRM-Onlus (Fondazione Internazionale di Ricerca in Medicina Onlus) for  
256 the continuous support.

257

## 258 **References**

259 Abufaraj, M., T. Iwata, S. Kimura, A. Haddad, H. Al-Ani, L. Abusubaih, M. Moschini, A. Briganti, P. I.  
260 Karakiewicz, and S. F. Shariat. 2021. "Differential Impact of Gonadotropin-Releasing Hormone  
261 Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic  
262 Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials." *Eur Urol* 79, no. 1 (Jan): 44-53.  
263 <https://dx.doi.org/10.1016/j.eururo.2020.06.002>.

264

265 Buckinx, F., F. Landi, M. Cesari, R. A. Fielding, M. Visser, K. Engelke, S. Maggi, E. Dennison, N. M. Al-Daghri,  
266 S. Allepaerts, J. Bauer, I. Bautmans, M. L. Brandi, O. Bruyère, T. Cederholm, F. Cerreta, A. Cherubini,  
267 C. Cooper, A. Cruz-Jentoft, E. McCloskey, B. Dawson-Hughes, J. M. Kaufman, A. Laslop, J.  
268 Petermans, J. Y. Reginster, R. Rizzoli, S. Robinson, Y. Rolland, R. Rueda, B. Vellas, and J. A. Kanis.  
269 2018. "Pitfalls in the Measurement of Muscle Mass: A Need for a Reference Standard." *J Cachexia*  
270 *Sarcopenia Muscle* 9, no. 2 (04): 269-278. <https://dx.doi.org/10.1002/jcsm.12268>.

271

272 Celestino Catão Da Silva, D., A. Nogueira De Almeida Vasconcelos, J. Cleto Maria Cerqueira, D. De Oliveira  
273 Cipriano Torres, A. C. Oliveira Dos Santos, H. De Lima Ferreira Fernandes Costa, and L. O. Bregieiro  
274 Fernandes Costa. 2013. "Endogenous Sex Hormones Are Not Associated with Subclinical  
275 Atherosclerosis in Menopausal Women." *Minerva Ginecol* 65, no. 3 (Jun): 297-302.

276

277 Cornford, P., J. Bellmunt, M. Bolla, E. Briers, M. De Santis, T. Gross, A. M. Henry, S. Joniau, T. B. Lam, M. D.  
278 Mason, H. G. van der Poel, T. H. van der Kwast, O. Rouvière, T. Wiegel, and N. Mottet. 2017. "Eau-  
279 Estro-Siog Guidelines on Prostate Cancer. Part Ii: Treatment of Relapsing, Metastatic, and  
280 Castration-Resistant Prostate Cancer." *Eur Urol* 71, no. 4 (04): 630-642.  
281 <https://dx.doi.org/10.1016/j.eururo.2016.08.002>.

282

283 Dalla Volta, A., C. Palumbo, S. Zamboni, G. Mazziotti, L. Triggiani, M. Zamparini, F. Maffezzoni, L. Rinaudo,  
284 M. Bergamini, N. Di Meo, I. Caramella, F. Valcamonico, P. Borghetti, A. Guerini, D. Farina, A.  
285 Antonelli, C. Simeone, and A. Berruti. 2023. "Heterogeneity in Regional Changes in Body  
286 Composition Induced by Androgen Deprivation Therapy in Prostate Cancer Patients: Potential  
287 Impact on Bone Health-the Blade Study." *J Endocrinol Invest* (Jul 17).  
288 <https://dx.doi.org/10.1007/s40618-023-02150-z>.

289

290 El Khoudary, S. R., N. Santoro, H. Y. Chen, P. G. Tepper, M. M. Brooks, R. C. Thurston, I. Janssen, S. D.  
291 Harlow, E. Barinas-Mitchell, F. Selzer, C. A. Derby, E. A. Jackson, D. McConnell, and K. A. Matthews.  
292 2016. "Trajectories of Estradiol and Follicle-Stimulating Hormone over the Menopause Transition  
293 and Early Markers of Atherosclerosis after Menopause." *Eur J Prev Cardiol* 23, no. 7 (May): 694-703.  
294 <https://dx.doi.org/10.1177/2047487315607044>.

295

296 Gera, S., T. C. Kuo, A. A. Gumerova, F. Korkmaz, D. Sant, V. DeMambro, K. Sudha, A. Padilla, G. Prevot, J.  
297 Munitz, A. Teunissen, M. M. T. van Leent, T. G. J.M Post, J. C. Fernandes, J. Netto, F. Sultana, E.  
298 Shelly, S. Rojekar, P. Kumar, L. Cullen, J. Chatterjee, A. Pallapati, S. Miyashita, H. Kannangara, M.

- 299 Bhongade, P. Sengupta, K. Ievleva, V. Muradova, R. Batista, C. Robinson, A. Macdonald, S.  
300 Hutchison, M. Saxena, M. Meseck, J. Caminis, J. Iqbal, M. I. New, V. Ryu, S. M. Kim, J. J. Cao, N.  
301 Zaidi, Z. A. Fayad, D. Lizneva, C. J. Rosen, T. Yuen, and M. Zaidi. 2022. "Fsh-Blocking Therapeutic for  
302 Osteoporosis." *Elife* 11 (Sep 20). <https://dx.doi.org/10.7554/eLife.78022>.
- 303  
304 Guligowska, A., Z. Chrzastek, M. Pawlikowski, M. Pięłowska, H. Pisarek, K. Winczyk, and T. Kostka. 2021.  
305 "Gonadotropins at Advanced Age - Perhaps They Are Not So Bad? Correlations between  
306 Gonadotropins and Sarcopenia Indicators in Older Adults." *Front Endocrinol (Lausanne)* 12: 797243.  
307 <https://dx.doi.org/10.3389/fendo.2021.797243>.
- 308  
309 Klotz, L., L. Boccon-Gibod, N. D. Shore, C. Andreou, B. E. Persson, P. Cantor, J. K. Jensen, T. K. Olesen, and F.  
310 H. Schröder. 2008. "The Efficacy and Safety of Degarelix: A 12-Month, Comparative, Randomized,  
311 Open-Label, Parallel-Group Phase Iii Study in Patients with Prostate Cancer." *BJU Int* 102, no. 11  
312 (Dec): 1531-8. <https://dx.doi.org/10.1111/j.1464-410X.2008.08183.x>.
- 313  
314 Liu, P., Y. Ji, T. Yuen, E. Rendina-Ruedy, V. E. DeMambro, S. Dhawan, W. Abu-Amer, S. Izadmehr, B. Zhou, A.  
315 C. Shin, R. Latif, P. Thangeswaran, A. Gupta, J. Li, V. Shnyder, S. T. Robinson, Y. E. Yu, X. Zhang, F.  
316 Yang, P. Lu, Y. Zhou, L. L. Zhu, D. J. Oberlin, T. F. Davies, M. R. Reagan, A. Brown, T. R. Kumar, S.  
317 Epstein, J. Iqbal, N. G. Avadhani, M. I. New, H. Molina, J. B. van Klinken, E. X. Guo, C. Buettner, S.  
318 Haider, Z. Bian, L. Sun, C. J. Rosen, and M. Zaidi. 2017. "Blocking Fsh Induces Thermogenic Adipose  
319 Tissue and Reduces Body Fat." *Nature* 546, no. 7656 (06 01): 107-112.  
320 <https://dx.doi.org/10.1038/nature22342>.
- 321  
322 Lizneva, D., A. Rahimova, S. M. Kim, I. Atabekov, S. Javaid, B. Alamoush, C. Taneja, A. Khan, L. Sun, R. Azziz,  
323 T. Yuen, and M. Zaidi. 2019. "Fsh Beyond Fertility." *Front Endocrinol (Lausanne)* 10: 136.  
324 <https://dx.doi.org/10.3389/fendo.2019.00136>.
- 325  
326 Margel, D., A. Peer, Y. Ber, L. Shavit-Grievink, T. Tabachnik, S. Sela, G. Witberg, J. Baniel, D. Kedar, W. C. M.  
327 Duivenvoorden, E. Rosenbaum, and J. H. Pinthus. 2019. "Cardiovascular Morbidity in a Randomized  
328 Trial Comparing GnRh Agonist and GnRh Antagonist among Patients with Advanced Prostate Cancer  
329 and Preexisting Cardiovascular Disease." *J Urol* 202, no. 6 (Dec): 1199-1208.  
330 <https://dx.doi.org/10.1097/JU.0000000000000384>.
- 331  
332 Mattick, L. J., J. W. Bea, L. Singh, K. M. Hovey, H. R. Banack, J. Wactawski-Wende, J. E. Manson, J. L. Funk,  
333 and H. M. Ochs-Balcom. 2022. "Serum Follicle-Stimulating Hormone and 5-Year Change in Adiposity  
334 in Healthy Postmenopausal Women." *J Clin Endocrinol Metab* 107, no. 8 (07 14): e3455-e3462.  
335 <https://dx.doi.org/10.1210/clinem/dgac238>.
- 336  
337 Mottet, N., J. Bellmunt, M. Bolla, E. Briers, M. G. Cumberbatch, M. De Santis, N. Fossati, T. Gross, A. M.  
338 Henry, S. Joniau, T. B. Lam, M. D. Mason, V. B. Matveev, P. C. Moldovan, R. C. N. van den Bergh, T.  
339 Van den Broeck, H. G. van der Poel, T. H. van der Kwast, O. Rouvière, I. G. Schoots, T. Wiegel, and P.  
340 Cornford. 2017. "Eau-Estro-Siog Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and  
341 Local Treatment with Curative Intent." *Eur Urol* 71, no. 4 (04): 618-629.  
342 <https://dx.doi.org/10.1016/j.eururo.2016.08.003>.
- 343  
344 Munir, J. A., H. Wu, K. Bauer, J. Bindeman, C. Byrd, I. M. Feuerstein, T. C. Villines, and A. J. Taylor. 2012.  
345 "The Perimenopausal Atherosclerosis Transition: Relationships between Calcified and Noncalcified



- 346 Coronary, Aortic, and Carotid Atherosclerosis and Risk Factors and Hormone Levels." *Menopause*  
347 19, no. 1 (Jan): 10-5. <https://dx.doi.org/10.1097/gme.0b013e318221bc8d>.
- 348  
349 Palumbo, C., A. Antonelli, L. Triggiani, A. Dalla Volta, F. Maffezzoni, S. Zamboni, P. Borghetti, L. Rinaudo, F.  
350 Valcamonico, R. Maroldi, S. M. Magrini, C. Simeone, A. Berruti, and Collaborators. 2021. "Changes  
351 in Body Composition and Lipid Profile in Prostate Cancer Patients without Bone Metastases Given  
352 Degarelix Treatment: The Blade Prospective Cohort Study." *Prostate Cancer Prostatic Dis* 24, no. 3  
353 (09): 852-859. <https://dx.doi.org/10.1038/s41391-021-00345-0>.
- 354  
355 Palumbo, C., A. Dalla Volta, S. Zamboni, G. Mazziotti, M. Zamparini, L. Triggiani, P. Borghetti, F. Maffezzoni,  
356 R. Bresciani, L. Rinaudo, F. Valcamonico, D. Farina, S. M. Magrini, A. Antonelli, C. Simeone, and A.  
357 Berruti. 2022. "Effect of Degarelix Administration on Bone Health in Prostate Cancer Patients  
358 without Bone Metastases. The Blade Study." *J Clin Endocrinol Metab* (Aug 16).  
359 <https://dx.doi.org/10.1210/clinem/dgac489>.
- 360  
361 Perneger, T. V. 1998. "What's Wrong with Bonferroni Adjustments." *BMJ* 316, no. 7139 (Apr 18): 1236-8.  
362 <https://dx.doi.org/10.1136/bmj.316.7139.1236>.
- 363  
364 Rojekar, S., A. R. Pallapati, J. Gimenez-Roig, F. Korkmaz, F. Sultana, D. Sant, C. M. Haeck, A. Macdonald, S.  
365 M. Kim, C. J. Rosen, O. Barak, M. Meseck, J. Caminis, D. Lizneva, T. Yuen, and M. Zaidi. 2023.  
366 "Development and Biophysical Characterization of a Humanized Fsh-Blocking Monoclonal Antibody  
367 Therapeutic Formulated at an Ultra-High Concentration." *Elife* 12 (Jun 19).  
368 <https://dx.doi.org/10.7554/eLife.88898>.
- 369  
370 Senapati, S., C. R. Gracia, E. W. Freeman, M. D. Sammel, H. Lin, C. Kim, R. J. Schwab, and G. W. Pien. 2014.  
371 "Hormone Variations Associated with Quantitative Fat Measures in the Menopausal Transition."  
372 *Climacteric* 17, no. 2 (Apr): 183-90. <https://dx.doi.org/10.3109/13697137.2013.845876>.
- 373  
374 Sowers, M., H. Zheng, K. Tomey, C. Karvonen-Gutierrez, M. Jannausch, X. Li, M. Yosef, and J. Symons. 2007.  
375 "Changes in Body Composition in Women over Six Years at Midlife: Ovarian and Chronological  
376 Aging." *J Clin Endocrinol Metab* 92, no. 3 (Mar): 895-901. <https://dx.doi.org/10.1210/jc.2006-1393>.
- 377  
378 Sun, L., Y. Peng, A. C. Sharrow, J. Iqbal, Z. Zhang, D. J. Papachristou, S. Zaidi, L. L. Zhu, B. B. Yaroslavskiy, H.  
379 Zhou, A. Zallone, M. R. Sairam, T. R. Kumar, W. Bo, J. Braun, L. Cardoso-Landa, M. B. Schaffler, B. S.  
380 Moonga, H. C. Blair, and M. Zaidi. 2006. "Fsh Directly Regulates Bone Mass." *Cell* 125, no. 2 (Apr  
381 21): 247-60. <https://dx.doi.org/10.1016/j.cell.2006.01.051>.
- 382  
383 Thurston, R. C., M. R. Sowers, B. Sternfeld, E. B. Gold, J. Bromberger, Y. Chang, H. Joffe, C. J. Crandall, L. E.  
384 Waetjen, and K. A. Matthews. 2009. "Gains in Body Fat and Vasomotor Symptom Reporting over  
385 the Menopausal Transition: The Study of Women's Health across the Nation." *Am J Epidemiol* 170,  
386 no. 6 (Sep 15): 766-74. <https://dx.doi.org/10.1093/aje/kwp203>.
- 387  
388 Vena, W., F. Carrone, A. Delbarba, O. Akpojiovbi, L. C. Pezzaioli, P. Facondo, C. Cappelli, L. Leonardi, L.  
389 Balzarini, D. Farina, A. Pizzocarò, A. G. Lania, G. Mazziotti, and A. Ferlin. 2022. "Body Composition,  
390 Trabecular Bone Score and Vertebral Fractures in Subjects with Klinefelter Syndrome." *J Endocrinol*  
391 *Invest* (Aug 28). <https://dx.doi.org/10.1007/s40618-022-01901-8>.

392

393 Visser, M., T. Fuerst, T. Lang, L. Salamone, and T. B. Harris. 1999. "Validity of Fan-Beam Dual-Energy X-Ray  
394 Absorptiometry for Measuring Fat-Free Mass and Leg Muscle Mass. Health, Aging, and Body  
395 Composition Study--Dual-Energy X-Ray Absorptiometry and Body Composition Working Group." *J*  
396 *Appl Physiol (1985)* 87, no. 4 (Oct): 1513-20. <https://dx.doi.org/10.1152/jappl.1999.87.4.1513>.

397

398 Zaidi, M., S. M. Kim, M. Mathew, F. Korkmaz, F. Sultana, S. Miyashita, A. A. Gumerova, T. Frolinger, O.  
399 Moldavski, O. Barak, A. Pallapati, S. Rojekar, J. Caminis, Y. Ginzburg, V. Ryu, T. F. Davies, D. Lizneva,  
400 C. J. Rosen, and T. Yuen. 2023. "Bone Circuitry and Interorgan Skeletal Crosstalk." *Elife* 12 (Jan 19).  
401 <https://dx.doi.org/10.7554/eLife.83142>.

402

403

**TABLE 1**

**Table 1** – Baseline relationships between FSH serum levels and BMD, bone turnover markers and body composition parameters.

	<b>FSH</b>	
	<b>Correlation coefficient</b>	<b>p</b>
<b>TOT BMD</b>	.240	.218
<b>BMD LEFT HIP</b>	.229	.240
<b>BMD L2-L4</b>	.148	.453
<b>CTX</b>	-.115	.560
<b>BONE ALP</b>	.001	.997
<b>TOT Fat (g)</b>	.274	.158
<b>Arm Fat (g)</b>	.363	.058
<b>Leg Fat (g)</b>	.330	.087
<b>Head Fat (g)</b>	.228	.244
<b>Trunk Fat (g)</b>	.249	.202
<b>TOT Lean (g)</b>	.216	.270
<b>Arm Lean (g)</b>	.166	.400
<b>Leg Lean (g)</b>	.197	.315
<b>Head Lean (g)</b>	.250	.199
<b>Trunk Lean (g)</b>	.190	.333
<b>ALMI (Appendicular Lean/Ht<sup>2</sup>)</b>	.269	.167
<b>ALMI/FBM</b>	-.184	.349
<b>Android/Gynoid Ratio</b>	-.024	.902

FSH: follicle-stimulating hormone; TOT: total; BMD: bone mineral density; CTX: C-terminal telopeptide of type I collagen; ALP: alkaline phosphatase; ALMI: appendicular lean mass index; Ht<sup>2</sup>: height squared; FBM: fat body mass.  
Data are Spearman R.

**TABLE 2**

**Table 2** – Relationships between FSH serum levels and BMD, bone turnover markers and body composition parameters after 12-months degarelix treatment.

	FSH at 6 months		FSH at 12 months	
	Correlation coefficient	p	Correlation coefficient	p
TOT BMD	-.039	.843	-.107	.595
BMD L2-L4	.102	.604	-.040	.844
BMD LEFT HIP	.030	.881	-.044	.829
CTX	.051	.796	.055	.785
BONE ALP	.174	.376	.227	.256
TOT Fat (g)	<b>.490</b>	<b>.008</b>	<b>.518</b>	<b>.006</b>
Arm Fat (g)	<b>.532</b>	<b>.004</b>	<b>.541</b>	<b>.004</b>
Leg Fat (g)	<b>.454</b>	<b>.015</b>	.328	.089
Head Fat (g)	.187	.341	.093	.644
Trunk Fat (g)	<b>.483</b>	<b>.009</b>	<b>.452</b>	<b>.018</b>
TOT Lean (g)	.029	.885	-.036	.859
Arm Lean (g)	.041	.837	.028	.889
Leg Lean (g)	-.176	.371	-.285	.149
Head Lean (g)	.086	.663	-.006	.977
Trunk Lean (g)	.161	.414	.021	.916
ALMI (Appendicular Lean/Ht <sup>2</sup> )	-.229	.241	-.265	.181
ALMI/FBM	<b>-.581</b>	<b>.001*</b>	<b>-.604</b>	<b>.001*</b>
Android/Gynoid Ratio	.142	.472	.231	.246

FSH: follicle-stimulating hormone; TOT: total; BMD: bone mineral density; CTX: C-terminal telopeptide of type I collagen; ALP: alkaline phosphatase; ALMI: appendicular lean mass index; Ht<sup>2</sup>: height squared; FBM: fat body mass.

Data are Spearman R.

\*Still significant after Bonferroni correction.

FIGURE 1  
Estimate differences in FSH





Figure 1 – Changes in mean follicle-stimulating hormone (FSH) serum levels from baseline to 6 and 12 months of degarelix treatment.




2a


FIGURE 2




2b



2c



2d



**Figure 2** – Relationship between follicle-stimulating hormone (FSH) serum levels and fat body mass (FBM) (**Fig. 2a**), arm fat body mass (**Fig. 2b**), trunk fat body mass (**Fig. 2c**) and appendicular lean mass index (ALMI)/FBM ratio (**Fig. 2d**) after 12-months degarelix treatment.

R = Spearman correlation coefficient; p = p-value.

**CONSORT DIAGRAM (source data [123547\\_0\\_data\\_set\\_3007640\\_s1333z.xls](#))**

